South Korean firms lay focus on immune cell therapy
29 April 2022 | News
Daewoong Pharmaceutical partners with UCI Therapeutics
Image credit: shutterstock
Daewoong Pharmaceutical has signed a joint research and development agreement with UCI Therapeutics (CEO Sooyoung Jung), a bioventure for CAR-NK cell therapy development.
Through this agreement, Daewoong Pharmaceutical and UCI Therapeutics plan to cooperate for the development of immune cell therapy based on the development and production technology of the two companies. Daewoong Pharmaceutical is expanding GMP (Good Manufacturing Practice) production facilities, and CMO (contract manufacturing organization, specialized in pharmaceuticals) production) will be in charge. The term of the agreement is 5 years from the date of signing.
UCI Therapeutics is a bioventure established in 2020 and is developing CAR-NK immune cell therapy based on NK cell engineering technology through gene introduction. CAR-NK is a next-generation immune anticancer cell therapy that combines CAR (Chimeric Antigen Receptor) that specifically responds to cancer cells and NK (Natural Killer) cells.
The ‘CellTaCT’ platform, a core technology of UCI Therapeutics, is a cell-based fusion therapy development platform to overcome the limitations of the existing combination therapy that administers cell therapy and anticancer drugs together. can be expected
